VEGFA and glioblastoma: The antiangiogenic agent bevacizumab (Avastin; Roche/Genentech, South San Francisco, CA), a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been investigated in the treatment of glioblastoma [2].